Logo image of 4AB.DE

ABBVIE INC (4AB.DE) Stock Fundamental Analysis

Europe - FRA:4AB - US00287Y1091 - Common Stock

195.4 EUR
-0.6 (-0.31%)
Last: 10/27/2025, 4:59:11 PM
Fundamental Rating

5

4AB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. There are concerns on the financial health of 4AB while its profitability can be described as average. 4AB is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year 4AB was profitable.
In the past year 4AB had a positive cash flow from operations.
4AB had positive earnings in each of the past 5 years.
4AB had a positive operating cash flow in each of the past 5 years.
4AB.DE Yearly Net Income VS EBIT VS OCF VS FCF4AB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

Looking at the Return On Assets, with a value of 2.71%, 4AB is in the better half of the industry, outperforming 78.08% of the companies in the same industry.
With an excellent Return On Invested Capital value of 13.81%, 4AB belongs to the best of the industry, outperforming 87.67% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for 4AB is in line with the industry average of 14.02%.
The last Return On Invested Capital (13.81%) for 4AB is above the 3 year average (13.67%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.71%
ROE N/A
ROIC 13.81%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
4AB.DE Yearly ROA, ROE, ROIC4AB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

Looking at the Profit Margin, with a value of 6.38%, 4AB belongs to the top of the industry, outperforming 82.19% of the companies in the same industry.
In the last couple of years the Profit Margin of 4AB has declined.
The Operating Margin of 4AB (31.27%) is better than 87.67% of its industry peers.
4AB's Operating Margin has declined in the last couple of years.
4AB has a Gross Margin of 70.93%. This is in the better half of the industry: 4AB outperforms 64.38% of its industry peers.
4AB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 31.27%
PM (TTM) 6.38%
GM 70.93%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
4AB.DE Yearly Profit, Operating, Gross Margins4AB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

3

2. Health

2.1 Basic Checks

4AB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 4AB has about the same amount of shares outstanding.
The number of shares outstanding for 4AB has been increased compared to 5 years ago.
The debt/assets ratio for 4AB is higher compared to a year ago.
4AB.DE Yearly Shares Outstanding4AB.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
4AB.DE Yearly Total Debt VS Total Assets4AB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

An Altman-Z score of 2.41 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
4AB has a better Altman-Z score (2.41) than 68.49% of its industry peers.
The Debt to FCF ratio of 4AB is 3.86, which is a good value as it means it would take 4AB, 3.86 years of fcf income to pay off all of its debts.
4AB's Debt to FCF ratio of 3.86 is amongst the best of the industry. 4AB outperforms 80.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.86
Altman-Z 2.41
ROIC/WACC1.71
WACC8.08%
4AB.DE Yearly LT Debt VS Equity VS FCF4AB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

4AB has a Current Ratio of 0.74. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of 4AB (0.74) is worse than 76.71% of its industry peers.
A Quick Ratio of 0.61 indicates that 4AB may have some problems paying its short term obligations.
4AB's Quick ratio of 0.61 is on the low side compared to the rest of the industry. 4AB is outperformed by 78.08% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.61
4AB.DE Yearly Current Assets VS Current Liabilites4AB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

4

3. Growth

3.1 Past

4AB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.03%.
Measured over the past 5 years, 4AB shows a small growth in Earnings Per Share. The EPS has been growing by 2.51% on average per year.
4AB shows a small growth in Revenue. In the last year, the Revenue has grown by 6.05%.
Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%

3.2 Future

The Earnings Per Share is expected to grow by 13.59% on average over the next years. This is quite good.
Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.22% on average per year.
EPS Next Y6.19%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
EPS Next 5Y13.59%
Revenue Next Year8.23%
Revenue Next 2Y8.64%
Revenue Next 3Y8.27%
Revenue Next 5Y7.22%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4AB.DE Yearly Revenue VS Estimates4AB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B
4AB.DE Yearly EPS VS Estimates4AB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 21.43 indicates a rather expensive valuation of 4AB.
4AB's Price/Earnings ratio is rather cheap when compared to the industry. 4AB is cheaper than 80.82% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.89. 4AB is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 15.60, 4AB is valued correctly.
Based on the Price/Forward Earnings ratio, 4AB is valued cheaply inside the industry as 86.30% of the companies are valued more expensively.
4AB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 21.43
Fwd PE 15.6
4AB.DE Price Earnings VS Forward Price Earnings4AB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 4AB is valued a bit cheaper than the industry average as 78.08% of the companies are valued more expensively.
84.93% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.98
EV/EBITDA 17.37
4AB.DE Per share data4AB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of 4AB may justify a higher PE ratio.
4AB's earnings are expected to grow with 16.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.46
PEG (5Y)8.53
EPS Next 2Y19.88%
EPS Next 3Y16.85%

6

5. Dividend

5.1 Amount

4AB has a Yearly Dividend Yield of 2.87%. Purely for dividend investing, there may be better candidates out there.
4AB's Dividend Yield is rather good when compared to the industry average which is at 10.16. 4AB pays more dividend than 95.89% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.31, 4AB pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.87%

5.2 History

The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
4AB.DE Yearly Dividends per share4AB.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2 4 6

5.3 Sustainability

4AB pays out 304.54% of its income as dividend. This is not a sustainable payout ratio.
4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP304.54%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
4AB.DE Yearly Income VS Free CF VS Dividend4AB.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
4AB.DE Dividend Payout.4AB.DE Dividend Payout, showing the Payout Ratio.4AB.DE Dividend Payout.PayoutRetained Earnings

ABBVIE INC

FRA:4AB (10/27/2025, 4:59:11 PM)

195.4

-0.6 (-0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-31 2025-10-31/bmo
Inst Owners74.42%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap345.19B
Revenue(TTM)58.33B
Net Income(TTM)3.72B
Analysts79.46
Price Target196.55 (0.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.87%
Yearly Dividend5.38
Dividend Growth(5Y)7.72%
DP304.54%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.04%
Min EPS beat(2)0.95%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.75%
Min EPS beat(4)0.02%
Max EPS beat(4)1.14%
EPS beat(8)7
Avg EPS beat(8)0.76%
EPS beat(12)9
Avg EPS beat(12)0.46%
EPS beat(16)11
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)0.93%
Min Revenue beat(2)0.63%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)5
Avg Revenue beat(16)-0.81%
PT rev (1m)3.45%
PT rev (3m)6.31%
EPS NQ rev (1m)-45.1%
EPS NQ rev (3m)-44.16%
EPS NY rev (1m)-12.38%
EPS NY rev (3m)-13.25%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)1.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.28%
Valuation
Industry RankSector Rank
PE 21.43
Fwd PE 15.6
P/S 6.87
P/FCF 21.98
P/OCF 20.79
P/B N/A
P/tB N/A
EV/EBITDA 17.37
EPS(TTM)9.12
EY4.67%
EPS(NY)12.52
Fwd EY6.41%
FCF(TTM)8.89
FCFY4.55%
OCF(TTM)9.4
OCFY4.81%
SpS28.43
BVpS-0.09
TBVpS-45.26
PEG (NY)3.46
PEG (5Y)8.53
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 2.71%
ROE N/A
ROCE 18.72%
ROIC 13.81%
ROICexc 14.74%
ROICexgc 370.81%
OM 31.27%
PM (TTM) 6.38%
GM 70.93%
FCFM 31.27%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.86
Debt/EBITDA 2.58
Cap/Depr 12.62%
Cap/Sales 1.79%
Interest Coverage 250
Cash Conversion 72.74%
Profit Quality 489.9%
Current Ratio 0.74
Quick Ratio 0.61
Altman-Z 2.41
F-Score6
WACC8.08%
ROIC/WACC1.71
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
EPS Next Y6.19%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
EPS Next 5Y13.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
Revenue Next Year8.23%
Revenue Next 2Y8.64%
Revenue Next 3Y8.27%
Revenue Next 5Y7.22%
EBIT growth 1Y13.81%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year20.95%
EBIT Next 3Y15.22%
EBIT Next 5Y11.27%
FCF growth 1Y-26.45%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-24.5%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / 4AB.DE FAQ

What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.


What is the valuation status of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.


How profitable is ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.


What are the PE and PB ratios of ABBVIE INC (4AB.DE) stock?

The Price/Earnings (PE) ratio for ABBVIE INC (4AB.DE) is 21.43 and the Price/Book (PB) ratio is -2190.33.


Can you provide the expected EPS growth for 4AB stock?

The Earnings per Share (EPS) of ABBVIE INC (4AB.DE) is expected to grow by 6.19% in the next year.